Literature DB >> 11152436

High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients.

A Marron1, J Carratalà, F Alcaide, A Fernández-Sevilla, F Gudiol.   

Abstract

The prevalence of resistance to cephalosporins among viridans-group streptococci causing 88 (18%) cases among 485 bacteraemias in neutropenic cancer patients was studied. Rates of resistance to ceftriaxone, ceftazidime, cefpirome and cefepime were 22, 53, 14 and 34%, respectively. Previous administration of beta-lactam therapy was the only factor significantly associated with bacteraemia due to cephalosporin-resistant strains; only 11 (16%) of 68 patients infected with cephalosporin-susceptible bacteria had received these antibiotics compared with 10 (50%) of 20 patients infected with cephalosporin-resistant bacteria (P = 0.0052).

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11152436     DOI： 10.1093/jac/47.1.87

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  7 in total

1.  Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000.

Authors:  Andrea S Gershon; Joyce C S de Azavedo; Allison McGeer; Krystyna I Ostrowska; Deirdre Church; Daryl J Hoban; Godfrey K M Harding; Karl Weiss; Lewis Abbott; Fiona Smaill; Marie Gourdeau; Gilles Murray; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model.

Authors:  Razieh Kebriaei; Seth A Rice; Kyle C Stamper; Ravin Seepersaud; Cristina Garcia-de-la-Maria; Nagendra N Mishra; Jose M Miro; Cesar A Arias; Truc T Tran; Paul M Sullam; Arnold S Bayer; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model.

Authors:  Seyedehameneh Jahanbakhsh; Nivedita B Singh; Juwon Yim; Razieh Kebriaei; Jordan R Smith; Katherine Lev; T T Tran; Warren E Rose; Cesar A Arias; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

4.  Breakthrough viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients receiving levofloxacin prophylaxis in a Japanese hospital.

Authors:  Muneyoshi Kimura; Hideki Araoka; Atsushi Yoshida; Hisashi Yamamoto; Masahiro Abe; Yuki Okamoto; Mitsuhiro Yuasa; Daisuke Kaji; Kosei Kageyama; Aya Nishida; Kazuya Ishiwata; Shinsuke Takagi; Go Yamamoto; Yuki Asano-Mori; Naoyuki Uchida; Akira Hishinuma; Koji Izutsu; Atsushi Wake; Shuichi Taniguchi; Akiko Yoneyama
Journal:  BMC Infect Dis       Date:  2016-08-05       Impact factor: 3.090

5.  Risk Factors for Viridans Group Streptococcal Bacteremia in Neutropenic and Non-neutropenic Patients: A Single Center Case-Case-Control Study.

Authors:  Augusto Dulanto Chiang; Ninet Sinaii; Tara N Palmore
Journal:  Open Forum Infect Dis       Date:  2017-12-02       Impact factor: 3.835

6.  Evaluation of Empiric Vancomycin for Fevers During High-dose Cytarabine Administration.

Authors:  Alex Hoover; Jessica A O Zimmerman; Sawyer Wiese; Arunkumar Modi
Journal:  J Pediatr Hematol Oncol       Date:  2021-10-01       Impact factor: 1.170

7.  Mechanistic Insights Into the Differential Efficacy of Daptomycin Plus β-Lactam Combinations Against Daptomycin-Resistant Enterococcus faecium.

Authors:  Razieh Kebriaei; Kyle C Stamper; Kavindra V Singh; Ayesha Khan; Seth A Rice; An Q Dinh; Truc T Tran; Barbara E Murray; Cesar A Arias; Michael J Rybak
Journal:  J Infect Dis       Date:  2020-10-01       Impact factor: 5.226
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.